Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ezetimibe/rosuvastatin + telmisartan - Navipharm

X
Drug Profile

Ezetimibe/rosuvastatin + telmisartan - Navipharm

Alternative Names: NVP-1805; Telmisartan+Ezetimibe/Rosuvastatin

Latest Information Update: 15 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Navipharm
  • Class Antihyperlipidaemics; Antihypertensives; Azetidines; Benzimidazoles; Benzoates; Fluorobenzenes; Propanols; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists; Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hypertension

Most Recent Events

  • 27 Apr 2023 Navipharm Corporation completes a phase I trial in Healthy volunteers in South Korea (PO) (NCT05354713)
  • 15 Mar 2022 Navipharm plans a phase III trial for Hypertension (Navipharm website, March 2022)
  • 07 Jan 2022 Navipharm completes a phase I trial in Hypertension (In volunteers) in South Korea (NCT04905342)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top